Latest Commercial Revenue News

AVITA Medical reported a strong 30% increase in Q4 2024 commercial revenue and amended its credit agreement with OrbiMed to adjust revenue covenants through 2026. The company is poised for significant growth with new product rollouts and expects profitability by year-end 2025.

AVITA Medical's Q4 2024 earnings reveal strong commercial growth alongside the launch of Cohealyx, a novel collagen-based skin substitute that promises to transform acute wound care.

AVITA Medical reported a robust 30% increase in Q4 2024 commercial revenue alongside key FDA clearances, setting the stage for ambitious growth in 2025.

IODM Limited has achieved a significant milestone in its UK Education segment, raising its minimum monthly revenue threshold by 50% to GBP75k and outperforming half-year revenue forecasts.

Spenda Limited has reported a record-breaking quarter with cash receipts soaring 160% year-on-year and payment volumes more than doubling, signaling strong momentum as it advances toward profitability.

Botanix Pharmaceuticals has initiated the commercial rollout of Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, with first prescriptions dispensed and a fully trained sales force deployed. The company anticipates meaningful revenue growth starting in the first quarter of 2025, backed by strong payer contracts and a robust cash position.

Knosys Limited reports a record Annual Recurring Revenue of $9.7 million, driven by major enterprise contract renewals, while gearing up for the March 2025 launch of its Libero Library App.

Mont Royal Resources Limited reported a stable cash position of $1.75 million at the end of December 2024, despite significant outflows on exploration activities during the quarter.